This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Witzig TE , White CA , Wiseman GA , Gordon LI , Emmanouilides C , Raubitschek A , Janakiraman N , Gutheil J , Schilder RJ , Spies S , Silverman DHS , Parker E , Grillo-Lopez AJ
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
Journal of Clinical Oncology. 1999 Dec;17(12) :3793-3803
AbstractPurpose: Yttrium-90 ibritumomab tiuxetan (IDEC-Y2B8) is a murine immunoglobulin G1 kappa monoclonal antibody that covalently binds MX-DTPA (tiuxetan), which chelates the radioisotope yttrium-90. The antibody targets CD20, a B- lymphocyte antigen. A multicenter phase I/II trial was conducted to compare two doses of unlabeled rituximab given before radiolabeled antibody, to determine the maximum- tolerated single dose of IDEC-Y2B8 that could be administered without stem-cell support, and to evaluate safety and efficacy. Patients and Methods: Eligible patients had relapsed or refractory (two prior regimens or anthracycline if low-grade disease) CD20(+) B-cell low-grade, intermediate-grade, or mantle-cell non-Hodgkin's lymphoma (NHL), There was no limit on bulky disease, and 59% had at least one mass greater than or equal to 5 cm. Results: The maximum-tolerated dose was 0.4 mCi/kg IDEC-Y2B8 (0.3 mCi/kg for patients with baseline platelet counts 100 to 149,000/mu L). The overall response rate for the intent-to-treat population (n = 51) was 67% (26% complete response [CR]; 41% partial response [PR]); for low- grade disease (n = 34), 82% (26% CR; 56% PR); for intermediate- grade disease (n = 14), 43%; and for mantle-cell disease (n = 3), 0%. Responses occurred in patients with bulky disease (greater than or equal to 7 cm; 41%) and splenomegaly (50%). Kaplan-Meier estimate of time ta disease progression in responders and duration of response is 12.9+ months and 11.7+ months, respectively Adverse events were primarily hematologic and correlated with baseline extent of marrow involvement with NHL and baseline platelet count. One patient (2%) developed an anti-antibody response (human antichimeric antibody/human antimouse antibody). Conclusion: These phase I/II data demonstrate that IDEC-Y2B8 radioimmunotherapy is a safe and effective alternative for outpatient therapy of patients with relapsed or refractory NHL. A phase III study is ongoing. J Clin Oncol 17:3793-3803. (C) 1999 by American Society of Clinical Oncology.
NotesTimes Cited: 95 English Article 262AJ J CLIN ONCOL